Coronavirus Update: Warp Speed Companies Grilled On Vaccine Safety, Price And Timelines
Two Companies Commit To Not-For-Profit Supply
House committee seeks reassurances on a range of issues, including the security of a US vaccines supply chain against a background of rising tensions with China.
You may also be interested in...
Capacity, Expertise Drive Korea's Emergence As COVID-19-Related Manufacturing Base
A series of major COVID-19-related manufacturing deals reached by South Korean firms indicate the country could emerge as a major base for the production of drugs and vaccines.
Pfizer’s US Contract Sets The Financial Bar For COVID-19 Vaccines
The US government’s order of 100 million doses for $1.95bn means the implied price for Pfizer/BioNtech's vaccine is $19.50 per dose. That could set a benchmark for solid near-term revenue and profitability for companies in the space.
Executives On The Move: Jubilant, Mithra And More
Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.